The Ivoclar Group has announced the release of the latest edition (Vol. 4) of its IPS e.max Scientific Report, according to a September 9, 2025, press release from the company. The report, which is intended to provide comprehensive information to practices and laboratories that value clinically proven long-term reliability, summarizes the research of more than 20 different studies to provide an overview of the clinical performance of the entire family of all-ceramic IPS e.max materials. Confirming documented survival rates of over 95%, the report demonstrates that IPS e.max is one of the most reliable restorative materials available.
Globally, IPS e.max has been used to place more than 230 million restorations, and with clinical data spanning as many as 17 years, the ceramic system is one of the most thoroughly evaluated ones in the industry. With a portfolio that includes a lithium disilicate glass-ceramic (IPS e.max Press and CAD), a high-strength zirconium oxide ceramic (IPS e.max ZirCAD), and a fluorapatite layering ceramic (IPS e.max Ceram), IPS e.max enables esthetic, long-lasting, and customized treatment approaches for single-tooth restorations, bridges, and implant-supported solutions in both analog and digital workflows.
According to the report, IPS e.max Press demonstrated a 96.5 % survival rate over 16.9 years, IPS e.max CAD demonstrated a 97.2 % survival rate over 10 years, and IPS e.max ZirCAD demonstrated a 99 % survival rate over 5 years. These materials facilitate predictable treatment planning, reduce the need for retreatment, and foster trust between dental practices, laboratories, and patients. Equally well suited for both analog and digital workflows, IPS e.max materials deliver high levels of accuracy, esthetics, and strength, particularly when harmonized with the complementary components, such as veneering ceramics, stains, and luting materials, that complete the system.
Register to download volume 4 of the IPS e.max Scientific Report.
